Gensciences is a China-based, globally oriented innovative pharmaceutical company for hemophilia. Relying on our leading long-acting biotechnology platform, we focus on the unmet clinical needs of patients with hemophilia and continue to iteratively develop hemophilia drugs with Global Best-In-Class potential，aiming to help hemophilia patients live a normal life.

Founded in 2019 and headquartered in Nantong, Jiangsu Province, Gensciences is a biopharmaceutical company integrating innovative drug discovery, clinical research, manufacturing, and commercialization. The company has Beijing R&D center, Zhengzhou R&D center, early commercial production base in Shanghai Zhangjiang. The company is currently constructing its headquarter and commercial production base, covering an area of 78 acres, in Nantong, Jiangsu.

Gensciences has four innovative drugs under clinical development and registration review at present.FRSW107 is the first long-acting recombinant coagulation factor VIII product in China and is currently under registration review.FRSW117 is the second global once-a-week ultra-long-acting recombinant coagulation factor VIII product and currently in Phase III clinical trial.SS109 is the world’s first ultra-long-acting recombinant activated factor VII product. Subjects in its Phase II clinical trial have completed the study and a Phase III clinical protocol is being discussed.SS327 is the world’s first ultra-long-acting recombinant coagulation factor IX product and has been approved for clinical trial in China. In the future, we will focus on developing longer-acting and safer bio-innovative drugs in the field of coagulation and metabolic diseases.